ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Nonrandomized and randomized trials of novel agents in advanced gastrointestinal neuroendocrine tumors (carcinoids)

Nonrandomized and randomized trials of novel agents in advanced gastrointestinal neuroendocrine tumors (carcinoids)
Agent Molecular target(s) Patients* Objective tumor response rate (%) Median TTP or PFS Reference
VEGF pathway inhibitors
Phase II studies
Bevacizumab VEGF 22 18 66 weeks Yao JC; 2008[1]
Sunitinib VEGFR-1, -2, -3; PDGFR-alpha, -beta; KIT; RET; CSF-1R; FLT3 41 2 10.2 months (TTP) Kulke MH; 2008[2]
Sorafenib VEGFR-2, PDGFR, FGFR-1, BRAF 50 7Δ 7.8 months Hobday TJ; 2007[3]
Pazopanib VEGFR-1, -2, -3; PDGFR-alpha, -beta; KIT 22 0 12.7 months Phan AT; 2015[4]
15 (GI tract) 9 10 months Grande E; 2015[5]
7 (lung, thymus) 3.4 months
Cabozantinib VEGFR-2, MET, RET, AXL 41 15 31.4 months Chan J; 2017[6]
Lenvatinib VEGFR-1, -2, -3; FGFR-1, -2, -3, -4 56 (GI tract) 16 15.7 months Capdevila J; 2021 (TALENT)[7]
Randomized trials
Octreotide + bevacizumab VEGF 214 12 16.6 months (PFS) Yao JC; 2017 (SWOG S-0518)[8]
versus  
Octreotide + interferon 213 4 15.4 months
Pazopanib VEGFR-1, -2, -3; PDGFR-alpha, -beta; KIT 97 2 11.6 months Bergsland EK; 2019 (ALLIANCE A021202)[9]
versus  
Placebo 74 0 8.5 months
Surufatinib VEGF-1,2,3; FGFR-1 129 10 9.2 months Xu J; 2020 (SANET-ep)[10]
versus      
Placebo 69 0 3.8 months
mTOR inhibitors
Phase II studies
Everolimus mTOR 30 17 63 weeks Yao JC; 2008[11]
Temsirolimus mTOR 21 5 6 months Duran I; 2006[12]
Randomized trials
Everolimus + octreotide LAR 216 2 16.4 months Pavel ME; 2011 (RADIANT2)[13]
versus
Placebo + octreotide LAR 213 2 11.3 months
Everolimus + BSC 205 2 11.0 months Yao JC; 2016 (RADIANT4)◊[14]
versus
Placebo + BSC 97 1 3.9 months

TTP: time to tumor progression; PFS: progression-free survival; VEGF: vascular endothelial growth factor; VEGFR: vascular endothelial growth factor receptor; PDGFR: platelet-derived growth factor receptor; KIT: stem cell factor receptor; RET: rearranged during transfection or glial cell-line derived neurotrophic factor; CSF-1R: colony-stimulating factor 1 receptor; FLT3: fms-like tyrosine kinase 3; FGFR: fibroblast growth factor receptor; GI: gastrointestinal; SWOG: Southwest Oncology Group; mTOR: mammalian target of rapamycin; LAR: long-acting release; BSC: best supportive care.

* Number of patients evaluable for efficacy endpoints.

¶ Patients also received treatment with octreotide.

Δ Confirmed.

◊ All patients had nonfunctioning neuroendocrine tumors of the lung or GI origin.
References:
  1. Yao JC, Phan A, Hoff PM. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008; 26:1316.
  2. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008; 26:3403.
  3. Hobday TJ, Rubin K, Holen J, et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. J Clinl Oncol 2007; 25:ASCO Annual Meeting Proceedings part I, abstract 4504.
  4. Phan AT, Halperin DM, Chan JA, et al. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. Lancet Oncol 2015; 16:695.
  5. Grande E, Capdevila J, Castellano D, et al. Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). Ann Oncol 2015; 26:1987.
  6. Chan J, Faris JE, Murphy JE, et al. Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET). J Clin Oncol 2017; suppl 4S:abstract 228.
  7. Capdevila J, Fazio N, Lopez C, et al. Lenvatinib in patients with advanced grade 1/2 pancreatic and gastrointestinal neuroendocrine tumors: Results of the phase II TALENT trial (GETNE 1509). J Clin Oncol 2021; May 4;JCO2003368. doi: 10.1200/JCO.20.03368. (epub ahead of print).
  8. Yao JC, Guthrie KA, Moran C, et al. Phase III prospective randomized comparison trial of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab in patients with advanced carcinoid tumors: SWOG S0518. J Clin Oncol 2017; 35:1695.
  9. Bergsland EK, Mahoney MR, Asmis TR, et al. Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202). J Clin Oncol 2019; 37:(suppl; abstr 4005).
  10. Xu J, Shen L, Zhou Z, et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2020; 21:1500.
  11. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008; 26:4311.
  12. Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006; 95:1148.
  13. Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011; 378:2005.
  14. Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 2016; 387:968.
Graphic 90847 Version 14.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟